company background image
NANO logo

Nanobiotix ENXTPA:NANO Stock Report

Last Price

€6.24

Market Cap

€294.0m

7D

-9.8%

1Y

86.8%

Updated

25 Feb, 2024

Data

Company Financials +

NANO Stock Overview

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

NANO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Nanobiotix S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nanobiotix
Historical stock prices
Current Share Price€6.24
52 Week High€10.40
52 Week Low€1.61
Beta1.29
1 Month Change-12.97%
3 Month Change19.31%
1 Year Change86.83%
3 Year Change-54.78%
5 Year Change-44.29%
Change since IPO0.65%

Recent News & Updates

Recent updates

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Apr 26
We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

May 11
Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Dec 06
Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Jun 04
Is Nanobiotix (EPA:NANO) Using Too Much Debt?

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22
How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Shareholder Returns

NANOFR BiotechsFR Market
7D-9.8%-0.6%2.3%
1Y86.8%-9.5%7.9%

Return vs Industry: NANO exceeded the French Biotechs industry which returned -9.5% over the past year.

Return vs Market: NANO exceeded the French Market which returned 7.9% over the past year.

Price Volatility

Is NANO's price volatile compared to industry and market?
NANO volatility
NANO Average Weekly Movement7.0%
Biotechs Industry Average Movement6.3%
Market Average Movement4.4%
10% most volatile stocks in FR Market9.5%
10% least volatile stocks in FR Market2.2%

Stable Share Price: NANO has not had significant price volatility in the past 3 months.

Volatility Over Time: NANO's weekly volatility has decreased from 25% to 7% over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
2003101Laurent Levyhttps://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. Fundamentals Summary

How do Nanobiotix's earnings and revenue compare to its market cap?
NANO fundamental statistics
Market cap€293.97m
Earnings (TTM)-€58.78m
Revenue (TTM)€6.74m

43.6x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NANO income statement (TTM)
Revenue€6.74m
Cost of Revenue€0
Gross Profit€6.74m
Other Expenses€65.52m
Earnings-€58.78m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.25
Gross Margin100.00%
Net Profit Margin-872.15%
Debt/Equity Ratio-90.6%

How did NANO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.